依洛尤单抗降低LDL-C后认知功能影响:FOURIER试验自报告认知分析
基于FOURIER试验的22,655例动脉粥样硬化性心血管病患者,在最终访视时完成ECog自报告认知调查。结果显示,依洛尤单抗组与安慰剂组报告认知下降的比例相似,总评分3.7%对3.6%(p=0.62),即使LDL-C降至<20 mg/dl的患者与LDL-C≥100 mg/dl者相比认知下降比例也无显著差异。
要点
- 依洛尤单抗联合他汀不增加患者自报告认知下降风险。
- LDL-C降至<20 mg/dl的患者认知下降比例与LDL-C≥100 mg/dl者相似。
- EBBINGHAUS试验已证实依洛尤单抗不影响客观认知测试表现。
核心结论
- 在最大耐受他汀基础上加用依洛尤单抗平均治疗2.2年,对患者自报告认知无影响,即使达到LDL-C<20 mg/dl亦如此。
研究设计与样本
- FOURIER为随机双盲安慰剂对照试验,纳入动脉粥样硬化性心血管病且LDL-C≥70 mg/dl或非高密度脂蛋白胆固醇≥100 mg/dl的患者。
- 最终访视时患者完成23项日常认知(ECog)量表自报告调查,比较试验结束时与开始时日常功能水平,评分1–4分。
- 共22,655例患者完成ECog,中位随访2.2年;按随机治疗组及4周时达到的LDL-C水平比较ECog评分。
主要发现
- 报告认知下降(ECog评分≥2)的比例安慰剂组与依洛尤单抗组总评分分别为3.6%与3.7%(p=0.62)。
- 记忆域报告下降比例安慰剂组5.8%对依洛尤单抗组6.0%;执行功能总域均为3.6%对3.7%。
- 达到LDL-C<20 mg/dl的2,338例患者与LDL-C≥100 mg/dl的3,613例患者相比,报告总认知评分下降比例分别为3.8%与4.5%(p=0.57)。
临床怎么用
- 对于动脉粥样硬化性心血管病患者,依洛尤单抗联合他汀降脂治疗无需担忧自报告认知不良反应。
- 将LDL-C降至极低水平(<20 mg/dl)未增加患者自报告认知下降风险。
局限性
- 认知评估为患者自报告调查,非客观神经心理学测试。
- 分析基于FOURIER试验人群,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The EBBINGHAUS (Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects) trial demonstrated that evolocumab added to a background statin did not affect cognitive performance in a subset of 1,204 patients enrolled in FOURIER (Further Cardiovascular Outcomes Research With PCSK9 inhibitors in Subjects With Elevated Risk). OBJECTIVES: The authors describe patient-reported cognition in the entire FOURIER trial using a self-survey. METHODS: FOURIER was a randomized, double-blind, placebo-controlled trial involving patients with atherosclerotic cardiovascular disease and low-density lipoprotein cholesterol (LDL-C) levels ≥70 mg/dl or non-high-density cholesterol ≥100 mg/dl despite statin therapy. At the final visit, patients completed a 23-item survey on memory and executive domains from the Everyday Cognition (ECog) scale. Patients compared their levels of everyday function at the end of the trial with their levels at the beginning and scored as 1 (no change or improvement), 2 (occasionally worse), 3 (consistently little worse), or 4 (consistently much worse). ECog scores were compared by the 2 randomized treatment arms and by achieved LDL-C at 4 weeks. RESULTS: A total of 22,655 patients completed ECog after a median duration of 2.2 years. The proportions of patients reporting cognitive decline (ECog score ≥2) at the end of the study were similar for placebo versus evolocumab, both for total score 3.6% versus 3.7% (p = 0.62) and for subdomains (memory, 5.8% vs. 6.0%; total executive, 3.6% vs. 3.7%). The proportion of patients reporting a decline in total cognitive score was similar among the 2,338 patients who achieved very low LDL-C levels (<20 mg/dl) compared to the 3,613 patients with LDL-C ≥100 mg/dl (3.8% vs. 4.5%, p = 0.57). CONCLUSIONS: The addition of evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an average of 2.2 years of treatment, even among patients who achieved LDL-C <20 mg/dl.
引用
- Gencer B, Mach F, Guo J, et al. Cognition After Lowering LDL-Cholesterol With Evolocumab. J Am Coll Cardiol. 2020. PMID: 32381158. doi:10.1016/j.jacc.2020.03.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。